No Data
Zhongtai: Innovative Drugs lead the market, pay attention to Q1 performance + policy catalysis.
In April, the pharmaceutical Sector is expected to continue its structural market trend, with Innovative Drugs as the main line and thematic opportunities rotating.
Earnings Miss: Luye Pharma Group Ltd. Missed EPS By 42% And Analysts Are Revising Their Forecasts
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
Overseas expansion is continuously being catalyzed, and the pharmaceutical stock market is gradually heating up. Institutions: China's "R&D premium" is being recognized globally.
① As of the time of writing, the Hang Seng Innovative Drugs Index has risen over 6%, with many Biomedical stocks in the A-share market hitting the ceiling limit. ② GTJA emphasizes that the centralized procurement rules are expected to be optimized, promoting marginal improvements in the pharmaceutical Sector. ③ Soochow believes that overseas buyers' attention to China's first in class opportunities has significantly increased.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
